NUVISAN GmbH with headquarters in Neu-Ulm, Germany, acquires with effect as of 1st of July 2016 a research and development site for Drug Metabolism and Pharmacokinetics (DPMK) in Grafing (near Munich) from Darmstadt-based Merck-KGaA. The research institute employs about 40 staff members. Continue reading